Canopy
COVID-19 (Prevention/Treatment)
Phase 3Positive Phase 3 trial results announced
Key Facts
Indication
COVID-19 (Prevention/Treatment)
Phase
Phase 3
Status
Positive Phase 3 trial results announced
Company
About Invivyd
Invivyd is on a mission to rapidly and continually deliver antibody-based therapies that keep pace with evolving viral threats, starting with COVID-19. The company employs a unique, integrated technology platform to develop best-in-class antibodies that are more potent and resistant to virus evolution than the natural immune response. Its strategic focus includes building a robust pipeline for prevention and treatment, with a lead asset authorized for emergency use and a Phase 3 candidate showing positive results. The leadership team comprises seasoned executives with deep experience in infectious disease drug development and commercialization.
View full company profileTherapeutic Areas
Other COVID-19 (Prevention/Treatment) Drugs
| Drug | Company | Phase |
|---|---|---|
| Lead mAb (name not specified) | Invivyd | Approved (EUA) |